Skip to Main Content

WASHINGTON — The Food and Drug Administration can’t escape questions about Aduhelm.

Patrizia Cavazzoni, one of the agency’s highest-ranking drug regulators, set out to testify before Congress Thursday on the intricacies of three looming funding bills crucial to the agency’s operations. But again and again, lawmakers grilled her about Biogen’s controversial Alzhiemer’s drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment